This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Novo Nordisk Stock Gains 14% in a Month: What Should Investors Do?
by Ahan Chakraborty
Despite competitive pressures in the obesity market, long-term investors may stay invested in NVO stock due to strong demand for its GLP-1 drugs.
NVOPositive Net Change LLYNegative Net Change AMGNPositive Net Change VKTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Kodiak Q1 Loss Wider Than Expected, Pipeline Development in Focus
by Zacks Equity Research
KOD reports a wider-than-expected loss for the first quarter of 2025. The company provides updates regarding its pipeline development plans.
HALOPositive Net Change KODNegative Net Change ALLONegative Net Change
biotechs earnings
Recursion Pharmaceuticals Plunges 22% in May: How to Play the Stock
by Ahan Chakraborty
Despite the current downward trend of RXRX, one should retain the stock for long-term gains due to the significant potential of its AI-driven drug discovery technology.
SNYNegative Net Change RHHBYNegative Net Change BAYRYPositive Net Change RXRXNegative Net Change
artificial-intelligence biotechnology biotechs medical pharmaceuticals
Septerna Stock Surges on Oral Obesity Drug Deal With Novo Nordisk
by Zacks Equity Research
SEPN is entitled to receive around $2.2 billion from NVO under the new collaboration deal, which aims to develop oral pills for obesity and other diseases.
NVOPositive Net Change LLYNegative Net Change AMGNPositive Net Change SEPNNegative Net Change
biotechs pharmaceuticals
AbbVie Secures FDA Nod for New ADC Drug Emrelis in Lung Cancer
by Zacks Equity Research
Following the approval, ABBV's Emrelis becomes the first FDA-approved therapy for previously treated advanced NSCLC patients with high c-Met protein overexpression.
ABBVNegative Net Change AGENPositive Net Change ADPTNegative Net Change
biotechs medical pharmaceuticals
5 Low Price-to-Book Value Stocks to Buy in May
by Kinjel Shah
The P/B ratio helps to identify low-priced stocks with high growth prospects. CNC, CVS, PFE, STNE and SAN are some such stocks.
PFEPositive Net Change CVSPositive Net Change CNCPositive Net Change SANPositive Net Change STNEPositive Net Change
biotechs medical pharmaceuticals
GSK Inks $2B Deal With Boston Pharmaceuticals to Buy Liver Disease Drug
by Zacks Equity Research
Through the Boston Pharma deal, GSK aims to strengthen its pipeline, as some of its key products are nearing the end of their exclusivity period.
GSKPositive Net Change NVSPositive Net Change ITOSNegative Net Change
biotechs medical pharmaceuticals
Fate Therapeutics' Q1 Earnings & Revenues Beat, Pipeline in Focus
by Zacks Equity Research
FATE incurs a narrower-than-expected loss in the first quarter. The company's innovative pipeline remains in focus.
HALOPositive Net Change FATENegative Net Change ALLONegative Net Change
biotechs earnings
EXEL Q1 Earnings Beat, 2025 Sales View Up as Cabometyx Drives Top Line
by Zacks Equity Research
Exelixis' first-quarter earnings and sales beat estimates as lead drug Cabometyx maintains momentum. The company raises its sales guidance for 2025.
BAYRYPositive Net Change EXELPositive Net Change EDITNegative Net Change ALLONegative Net Change
biotechnology biotechs earnings medical oncology-screening pharmaceuticals
Allogene's Q1 Earnings In Line With Estimates, Sales Nil
by Zacks Equity Research
ALLO's first-quarter earnings match estimates. Devoid of marketed products, the company records nil sales in the quarter.
AGENPositive Net Change ADPTNegative Net Change ALLONegative Net Change
biotechs cell-therapy earnings medical
Xenon Q1 Loss Narrower Than Expected, Pipeline Development in Focus
by Zacks Equity Research
XENE incurs narrower-than-estimated first-quarter 2025 loss. Studies on lead candidate, azetukalner, in epilepsy and MDD are progressing well.
HALOPositive Net Change NBIXNegative Net Change XENENegative Net Change ALLONegative Net Change
biotechs earnings
Bayer Q1 Earnings Beat Estimates, Crop Science Unit Hurts Sales
by Zacks Equity Research
BAYRY's first-quarter earnings beat expectations. Revenues miss estimates, mainly due to lower sales of its products in the Crop Science division.
REGNPositive Net Change AZNNegative Net Change JNJPositive Net Change BAYRYPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Editas Q1 Loss Narrower Than Expected, Revenues Increase Y/Y
by Zacks Equity Research
EDIT announces encouraging first-quarter 2025 results, as both earnings and revenues beat estimates.
AZNNegative Net Change BAYRYPositive Net Change EDITNegative Net Change ALLONegative Net Change
biotechnology biotechs crispr earnings medical pharmaceuticals
RHHBY to Invest $1.25B to Boost Manufacturing Footprint in US
by Zacks Equity Research
Roche plans to invest over $700 million in setting up a new plant in North Carolina and up to $550 million in expanding its Indianapolis diagnostics hub.
NVSPositive Net Change RHHBYNegative Net Change JNJPositive Net Change LLYNegative Net Change
biotechs medical pharmaceuticals
Drug Stocks Recover as Trump's Order Proves Not as Bad as Feared
by Kinjel Shah
President Trump issues an executive order that will push drugmakers to offer prescription drugs to U.S. cash-pay consumers at lower prices.
PFEPositive Net Change MRKPositive Net Change LLYNegative Net Change AMGNPositive Net Change ABBVNegative Net Change
biotechs pharmaceuticals
Pharma Stocks Hit by Trump's Vow to Cut US Prescription Drug Costs
by Kinjel Shah
The price cuts would see that U.S. consumers pay the same amount as the nation that pays the lowest price for that drug.
JNJPositive Net Change PFEPositive Net Change MRKPositive Net Change LLYNegative Net Change AMGNPositive Net Change
biotechs pharmaceuticals
RDY Q4 Earnings Beat Estimates, Generics Revenues Rise Y/Y, Stock Up
by Zacks Equity Research
Dr. Reddy's stock is up on encouraging fiscal fourth-quarter 2025 results, wherein both earnings and revenues beat estimates, driven by higher global generic sales.
RDYPositive Net Change BAYRYPositive Net Change ALLONegative Net Change ALVOPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
J&J Oral Psoriasis Drug Meets Primary Goal in Late-Stage Study
by Zacks Equity Research
Data from a late-stage study shows that treatment with JNJ's icotrokinra helps achieve significant skin clearance in hard-to-treat scalp and genital psoriasis.
BMYPositive Net Change JNJPositive Net Change PTGXPositive Net Change
biotechs medical pharmaceuticals
Kymera' s Q1 Loss Narrower Than Expected, Pipeline Progress Encouraging
by Zacks Equity Research
Kymera reports a narrower-than-expected loss for the first quarter of 2025. The company expects the current cash balance to provide a runway into the first half of 2028.
SNYNegative Net Change BEAMNegative Net Change ADMANegative Net Change KYMRNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Prothena Q1 Earnings Miss Estimates, Focus on Key Readouts in 2025
by Zacks Equity Research
PRTA posts a wider-than-expected first-quarter loss. Investors will focus on important readouts on birtamimab and PRX012 later in 2025.
RHHBYNegative Net Change BMYPositive Net Change NVOPositive Net Change PRTANegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Insmed's Q1 Loss Wider Than Expected, Sales Match Estimates
by Zacks Equity Research
INSM posts wider-than-expected loss in the first quarter. It reiterates the 2025 sales outlook for Arikayce in the range of $405-$425 million.
BEAMNegative Net Change INSMPositive Net Change ADPTNegative Net Change
biotechs earnings gene-therapy medical
Intellia's Q1 Loss Narrower Than Expected, Pipeline in Focus, Stock Up
by Zacks Equity Research
NTLA reports better-than-expected first-quarter 2025 results. The company provides updates on its pipeline candidates. Shares rise.
REGNPositive Net Change BEAMNegative Net Change ANIPPositive Net Change NTLANegative Net Change
biotechs earnings
Pacira BioSciences Q1 Earnings Beat, Revenues Miss Estimates
by Zacks Equity Research
PCRX reports mixed first-quarter results, wherein earnings beat estimates but revenues miss the same. Exparel sales witness weak year-over-year growth.
BAYRYPositive Net Change BEAMNegative Net Change PCRXPositive Net Change ADMANegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
RCKT's Q1 Loss Narrower Than Expected, Pipeline in Focus
by Zacks Equity Research
Rocket Pharmaceuticals incurs a narrower-than-expected first-quarter 2025 loss. The company provides updates on its pipeline candidates.
BAYRYPositive Net Change BEAMNegative Net Change ADMANegative Net Change RCKTNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
NVAX Stock Gains 12% on Q1 Earnings & Sales Beat, '25 Sales View Up
by Zacks Equity Research
Novavax posts encouraging first-quarter results on the back of an additional $603 million in revenues recognized from the termination of two advanced purchase agreements.
SNYNegative Net Change NVAXNegative Net Change BEAMNegative Net Change ADPTNegative Net Change
biotechs earnings medical pharmaceuticals vaccines